Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8378-8387

  Anichini, Andrea ^a   Molla, Alessandra ^a   Vegetti, Claudia ^a   Bersani, Ilaria ^a   Zappasodi, Roberta ^a   Arienti, Flavio ^a   Ravagnani, Fernando ^a   Maurichi, Andrea ^a   Patuzzo, Roberto ^a   Santinami, Mario ^a   Pircher, Hanspeter ^b   Di Nicola, Massimo ^a   Mortarini, Roberta ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PERFORIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BLOOD; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EFFECTOR CELL; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; UPREGULATION;

BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOLOGIC MEMORY; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PHENOTYPE; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 78449274156     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2028     Document Type: Article

References (46)

1. Romero P, Cerottini JC, Speiser DE. The human T cell response to melanoma antigens. Adv Immunol 2006;92:187-224. (Pubitemid 44834534)
2. + T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J Immunol 2003;171:2134-41.
3. + T cells at tumor site in spite of antitumor immunity to self antigens in human metastatic melanoma. Cancer Res 2003;63:2535-45.
4. + T lymphocytes. J Immunol 2007;178:4112-9.
5. Koch S, Larbi A, Derhovanessian E, et al. Multiparametric flow cytometric analysis of CD4 and CD8 T-cell subsets in young and old people. Immunity & Ageing 2008;5:1-12.
6. Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73A:975-83.
7. + T-cell differentiation. Ann N Y Acad Sci 2010;1183:251-66.
8. Joshi NS, Cui W, Chandele A, et al. Inflammation directs memory precursors and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 2007;27:281-95.
9. + T-cell differentiation. Curr Opin Immunol 2009;21:291-7.
10. + T-cell differentiation during viral infection. Immunity 2007;27:393-405.
11. Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Rα expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 2010; 32:91-103.
12. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439: 682-7. (Pubitemid 43237609)
13. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-44.
14. Voehringer D, Blaser C, Brawand P, Raulet DH, Hanke T, Pircher H. Viral infections induce abundant numbers of senescent CD8 T cells. J Immunol 2001;167:4838-43. (Pubitemid 33009711)
15. + T lymphocytes during active, latent and resolved infection and its relation with CD57. J Immunol 2005;174: 6088-94.
16. + T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-22.
17. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009;30:616-25.
18. + regulatory T cells, their suppressive mechanisms and regulation in cancer. Hum Immunol 2008;69:811-8.
19. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-64.
20. Kmieciak M, Gowda M, Graham L, et al. Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009;7:89-96.
21. Ahmadzadeh M, Antony PA, Rosenberg SA. IL-2 and IL-15 mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells. J Immunother 2007;30:294-302. (Pubitemid 46586645)
22. Mortarini R, Vegetti C, Molla A, et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009;15:4085-94.
23. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectin-like receptor G1 (KLRG1). Blood 2002;100:3698-702.
24. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
25. Morrison J, Elvin J, Latron F, et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLAA2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol 1992;22:903-7.
26. Ahmadzadeh M, Felipe-Silva A, Heemskerj B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008;112:4953-60.
27. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
28. + suppressive T cells in colorectal cancer tissue. Gut 2009;58:520-9.
29. + regulatory T-cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 2007;104:8029-34.
30. + regulatory T cells by continuous antigen stimulation. Eur J Immunol 2008;38:640-6.
31. + T cells upon antigen recognition in vitro. J Immunol 2007;179:1039-48.
32. Grosso JF, Goldberg MV, Getnet D, et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol 2009;182:6659-69.
33. + T cells. J Immunol 2004;172:7306-14.
34. Cruz-Guilloty F, Pipkin ME, Djuretic IM, et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J Exp Med 2009;206:51-9.
35. Lefrancois L, Obar JJ. Once a killer, always a killer: from cytotoxic T cell to memory cell. Immunol Rev 2010;235:206-18.
36. + T-cell differentiation. Immunol Rev 2010;235:219-33.
37. + T-cell differentiation. Intern Immunol 2010;22:619-25.
38. Kryczek I, Liu R, Wang G, et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69: 3995-4000.
39. + regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-57.
40. - T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006;67: 1-12.
41. + regulatory thymocytes. Blood 2003;102:4107-14.
42. + T cells. J Immunol 2009;182:2124-30.
43. + T cells. Blood 2003;101:2711-20.
44. + T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 2007;8:743-52.
45. + T-cell recruitment. Cancer Res 2009;69:3077-85.
46. Sensi M, Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res 2006; 12:5023-32.